Analysts Offer Insights on Technology Companies: Asure (ASUR), Docebo (DCBO) and ServiceNow (NOW)
There’s a lot to be optimistic about in the Technology sector as 3 analysts just weighed in on Asure (ASUR – Research Report), Docebo (DCBO – Research Report) and ServiceNow (NOW – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Asure (ASUR)
Lake Street analyst Eric Martinuzzi maintained a Buy rating on Asure today and set a price target of $13.00. The company’s shares closed last Tuesday at $9.18.
According to TipRanks.com, Martinuzzi is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Asure with a $16.70 average price target, implying a 70.4% upside from current levels. In a report issued on January 13, Needham also maintained a Buy rating on the stock with a $15.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Docebo (DCBO)
In a report released today, Suthan Sukumar from Stifel Nicolaus maintained a Buy rating on Docebo, with a price target of $34.00. The company’s shares closed last Tuesday at $19.01.
According to TipRanks.com, Sukumar is ranked #11278 out of 12040 analysts.
Docebo has an analyst consensus of Strong Buy, with a price target consensus of $33.98, representing a 77.0% upside. In a report released yesterday, Craig-Hallum also maintained a Buy rating on the stock.
ServiceNow (NOW)
In a report released today, Brian Schwartz from Oppenheimer maintained a Buy rating on ServiceNow, with a price target of $175.00. The company’s shares closed last Tuesday at $125.40.
According to TipRanks.com, Schwartz is a 4-star analyst with an average return of
Currently, the analyst consensus on ServiceNow is a Strong Buy with an average price target of $214.81, implying a 69.7% upside from current levels. In a report issued on January 6, Arete Research also upgraded the stock to Buy with a $200.00 price target.
